1. Home
  2. NBN vs GERN Comparison

NBN vs GERN Comparison

Compare NBN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBN

Northeast Bank

HOLD

Current Price

$125.57

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.28

Market Cap

911.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBN
GERN
Founded
1872
1990
Country
United States
United States
Employees
234
258
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
911.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NBN
GERN
Price
$125.57
$1.28
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
$130.50
$2.17
AVG Volume (30 Days)
115.9K
8.7M
Earning Date
04-27-2026
05-06-2026
Dividend Yield
0.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.77
$26.91
Revenue Next Year
$18.72
$43.75
P/E Ratio
$11.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$80.75
$1.04
52 Week High
$142.31
$2.01

Technical Indicators

Market Signals
Indicator
NBN
GERN
Relative Strength Index (RSI) 51.99 38.42
Support Level $127.84 $1.24
Resistance Level $138.66 $1.30
Average True Range (ATR) 5.66 0.08
MACD -0.73 -0.02
Stochastic Oscillator 48.31 16.13

Price Performance

Historical Comparison
NBN
GERN

About NBN Northeast Bank

Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: